Development of an algorithm for production of inactivated arbovirus antigens in cell culture

Journal of Virological Methods

Volumn 208, Issue , 2014, Pages 66-78

  Goodman, C H ^a   Russell, B J ^a   Velez, J O ^a   Laven, J J ^a   Nicholson, W L ^a   Bagarozzi, D A ^b   Moon, J L ^b   Bedi, K ^b   Johnson, B W ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antigen; Arbovirus; Beta propiolactone; Gamma irradiation; Immunoglobulin M antibody capture enzyme linked immunosorbent assay (MAC ELISA)

Indexed keywords

ARBOVIRUS ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ALGORITHM; ANIMAL CELL; ARBOVIRUS; ARTICLE; BUNYAVIRUS; CELL CULTURE; CONCEPTUAL FRAMEWORK; CONTROLLED STUDY; CULTURE OPTIMIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLAVIVIRUS; M ANTIBODY CAPTURE ENZYME LINKED IMMUNOSORBENT ASSAY; NONHUMAN; PRIORITY JOURNAL; STANDARDIZATION; TOGAVIRUS; ULTRACENTRIFUGATION; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS INACTIVATION; VIRUS STRAIN; ANIMAL; BUNYAVIRIDAE; CHEMISTRY; CULTURE TECHNIQUE; DIAGNOSTIC USE; FLAVIVIRIDAE; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; PHYSIOLOGY; PROCEDURES; STANDARD; TOGAVIRIDAE; VIRUS CULTURE;

ALGORITHMS; ANIMALS; ANTIGENS, VIRAL; BUNYAVIRIDAE; CELL CULTURE TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLAVIVIRIDAE; HUMANS; REFERENCE STANDARDS; TOGAVIRIDAE; VIRUS CULTIVATION; VIRUS INACTIVATION;

EID: 84906258400     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2014.07.030     Document Type: Article

References (39)

1. Amanna I.J., Raue H.P., Slifka M.K. Development of a new hydrogen peroxide-based vaccine platform. Nat. Med. 2012, 18:974-979.
2. Barteling S.J. Development and performance of inactivated vaccines against foot and mouth disease. Rev. Sci. Tech. 2002, 21:577-588.
3. Beaty B., Calisher C., Shope R. Arboviruses. Diagnostic procedures for viral, rickettsial, and chlamydial infections 1995, 189-212. American Public Health Association, Washington, DC. E. Lennette, D. Lennette, E. Lennette (Eds.).
4. Bonnafous P., Nicolai M.C., Taveau J.C., Chevalier M., Barriere F., Medina J., Le Bihan O., Adam O., Ronzon F., Lambert O. Treatment of influenza virus with beta-propiolactone alters viral membrane fusion. Biochim. Biophys. Acta 2014, 1838:355-363.
5. Brand O.M., Allen W.P. Preparation of noninfectious arbovirus antigens. Appl. Microbiol. 1970, 20:298-302.
6. Brown F. Inactivation of viruses by aziridines. Vaccine 2001, 20:322-327.
7. Burke D., Monath T.P. Flaviviruses. Fields Virology 2001, 1043-1125. Lippincott Williams and Wilkins, Philadelphia. 4th ed. D. Knipe, P. Howley (Eds.).
8. Centers for Disease Control and Prevention International Catalog of Arboviruses Including Certain Other Viruses of Vertebrates 2014, Available at www.n.cdc.gov/arbocat/index.asp.
9. Cleton N., Koopmans M., Reimerink J., Godeke G.J., Reusken C. Come fly with me: review of clinically important arboviruses for global travelers. J. Clin. Virol. 2012, 55:191-203.
10. Earley E., Johnson K. The lineage of the Vero, Vero 76 and its clone C1008 in the United States. Vero Cells: Origin Proterties and Biomedical Application 1988, Chiba University, Tokyo. B. Simizu, T. Terasima (Eds.).
11. Ei Khoury M.Y., Camargo J.F., Wormser G.P. Changing epidemiology of Powassan encephalitis in North America suggests the emergence of the deer tick virus subtype. Expert Rev. Anti Infect Ther. 2013, 11:983-985.
12. French G.R., McKinney R.W. Use of beta-propiolactone in preparation of inactivated arbovirus serologic test antigens. J. Immunol. 1964, 92:772-778.
13. Gubler D.J. The global emergence/resurgence of arboviral diseases as public health problems. Arch. Med. Res. 2002, 33:330-342.
14. Hearn H.J., Dawson F.W. Comparative effects of beta-propiolactone on mice, mouse-derived cell cultures, and Venezuelan equine encephalomyelitis virus. Appl. Microbiol. 1961, 9:278-282.
15. Hiatt C.W. Kinetics of the inactivation of viruses. Bacteriol. Rev. 1964, 28:150-163.
16. Johnson A.J., Martin D.A., Karabatsos N., Roehrig J.T. Detection of anti-arboviral immunoglobulin G by using a monoclonal antibody-based capture enzyme-linked immunosorbent assay. J. Clin. Microbiol. 2000, 38:1827-1831.
17. Johnson A.J., Noga A.J., Kosoy O., Lanciotti R.S., Johnson A.A., Biggerstaff B.J. Duplex microsphere-based immunoassay for detection of anti-West Nile virus and anti-St. Louis encephalitis virus immunoglobulin m antibodies. Clin. Diagn. Lab. Immunol. 2005, 12:566-574.
18. Lanciotti R.S., Kosoy O.L., Laven J.J., Panella A.J., Velez J.O., Lambert A.J., Campbell G.L. Chikungunya virus in US travelers returning from India, 2006. Emerg. Infect. Dis. 2007, 13:764-767.
19. Lanciotti R.S., Kosoy O.L., Laven J.J., Velez J.O., Lambert A.J., Johnson A.J., Stanfield S.M., Duffy M.R. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg. Infect. Dis. 2008, 14:1232-1239.
20. Lanciotti R.S., Roehrig J.T., Deubel V., Smith J., Parker M., Steele K., Crise B., Volpe K.E., Crabtree M.B., Scherret J.H., Hall R.A., MacKenzie J.S., Cropp C.B., Panigrahy B., Ostlund E., Schmitt B., Malkinson M., Banet C., Weissman J., Komar N., Savage H.M., Stone W., McNamara T., Gubler D.J. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 1999, 286:2333-2337.
21. Lawrence S.A. Beta-propiolactone: viral inactivation in vaccines and plasma products. PDA J. Pharm. Sci. Technol. 2000, 54:209-217.
22. Logrippo G.A. Investigations of the use of beta-propiolactone in virus inactivation. Ann. N. Y. Acad. Sci. 1960, 83:578-594.
23. Martin D.A., Muth D.A., Brown T., Johnson A.J., Karabatsos N., Roehrig J.T. Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J. Clin. Microbiol. 2000, 38:1823-1826.
24. Monath T.P., Heinz F. Flaviviruses. Fields Virology 1996, 1043-1125. Lippincott Williams and Wilkins, Philadelphia. D. Knipe, P. Howley (Eds.).
25. Monath T.P., Lee C.K., Julander J.G., Brown A., Beasley D.W., Watts D.M., Hayman E., Guertin P., Makowiecki J., Crowell J., Levesque P., Bowick G.C., Morin M., Fowler E., Trent D.W. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 2010, 28:3827-3840.
26. Nims R.W., Gauvin G., Plavsic M. Gamma irradiation of animal sera for inactivation of viruses and mollicutes-a review. Biologicals 2011, 39:370-377.
27. Piret J., Desormeaux A., Bergeron M.G. Sodium lauryl sulfate, a microbicide effective against enveloped and nonenveloped viruses. Curr. Drug Targets 2002, 3:17-30.
28. Piret J., Roy S., Gagnon M., Landry S., Desormeaux A., Omar R.F., Bergeron M.G. Comparative study of mechanisms of herpes simplex virus inactivation by sodium lauryl sulfate and n-lauroylsarcosine. Antimicrob. Agents Chemother. 2002, 46:2933-2942.
29. Powers A.M., Brault A.C., Tesh R.B., Weaver S.C. Re-emergence of Chikungunya and O'nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. J. Gen. Virol. 2000, 81:471-479.
30. Rosenberg R., Johansson M.A., Powers A.M., Miller B.R. Search strategy has influenced the discovery rate of human viruses. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:13961-13964.
31. Sabin A. The St. Louis and Japanese B types of epidemic encephalitis: development of noninfective vaccines. J. Am. Med. Assoc. 1943, 122:10.
32. Solomon T., Winter P.M. Neurovirulence and host factors in flavivirus encephalitis-evidence from clinical epidemiology. Arch. Virol. Suppl. 2004, 161-170.
33. Staples J.E., Breiman R.F., Powers A.M. Chikungunya fever: an epidemiological review of a re-emerging infectious disease. Clin. Infect. Dis. 2009, 49:942-948.
34. Thibodeaux B.A., Liss N.M., Panella A.N., Roehrig J.T. Development of a human-murine chimeric immunoglobulin M for use in the serological detection of human alphavirus antibodies. Clin. Vaccine Immunol. 2011, 18:2181-2182.
35. Uittenbogaard J.P., Zomer B., Hoogerhout P., Metz B. Reactions of beta-propiolactone with nucleobase analogues, nucleosides, and peptides: implications for the inactivation of viruses. J. Biol. Chem. 2011, 286:36198-36214.
36. Weaver S.C. Host range, amplification and arboviral disease emergence. Arch. Virol. Suppl. 2005, 33-44.
37. WHO WHO-recommended standards for surveillance of selected vaccine-preventable diseases 2003.
38. Wong S.J., Boyle R.H., Demarest V.L., Woodmansee A.N., Kramer L.D., Li H., Drebot M., Koski R.A., Fikrig E., Martin D.A., Shi P.Y. Immunoassay targeting nonstructural protein 5 to differentiate West Nile virus infection from dengue and St. Louis encephalitis virus infections and from flavivirus vaccination. J. Clin. Microbiol. 2003, 41:4217-4223.
39. Wong S.J., Demarest V.L., Boyle R.H., Wang T., Ledizet M., Kar K., Kramer L.D., Fikrig E., Koski R.A. Detection of human anti-flavivirus antibodies with a west nile virus recombinant antigen microsphere immunoassay. J. Clin. Microbiol. 2004, 42:65-72.